Business
Update regarding Nominated Adviser and Broker
Update regarding Nominated Adviser and Broker.
About this update from Skinbiotherapeutics Plc
[{"type":"text","content":"\n\n22 November 2023\n \n \n \nSkinBioTherapeutics plc\n \n(\"SkinBioTherapeutics\" or \"the Company\")\n \nUpdate regarding Nominated Adviser and Broker\n \nSkinBioTherapeutics plc, (AIM: SBTX, or the \"Company\"), the life science business focused on skin health, announces that, following the completion of the all-share merger between Cavendish Securities plc (previously named Cenkos Securities plc) and Cavendish Financial plc (previously named finnCap Group plc), and as a consequence of internal reorganisation within the Cavendish Group, the Company has changed its Nominated Adviser and Broker from Cavendish Securities plc to Cavendish Capital Markets Limited.\n \n \nFor more information please contact:\n\n\n\n\n\nSkinBioTherapeutics plc\nStuart J. Ashman, CEO\nManprit Randhawa, CFO\n \n\n\nTel: +44 (0) 191 495 7325\n\n\n\n\nCavendish Capital Markets Limited\n(Nominated Adviser & Broker)\nGiles Balleny, Dan Hodkinson (Corporate Finance)\nCharlie Combe (Broking)\nDale Bellis, Tamar Cranford-Smith (Sales)\n \n\n\n Tel: +44 (0) 20 7220 0500\n\n\n\n\nInstinctif Partners (financial press)\nMelanie Toyne-Sewell / Adam Loudon / Jack Kincade\n\n\nTel: +44 (0) 20 7457 2020\[email protected]\n\n\n\n\n\nNotes to Editors\nAbout SkinBioTherapeutics plc\nSkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix®, is based upon discoveries made by Professor Catherine O'Neill and Professor Andrew McBain.\nThe Company is targeting a number of skin healthcare sectors, the most advanced of which are cosmetic skincare and food supplements to modulate the immune system by harnessing the gut-skin axis. In each area...